Pulmatrix (NASDAQ:PULM) Shares Cross Below 50 Day Moving Average – Here’s Why

Posted by Caroline Horne on May 28th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as low as $1.31. Pulmatrix shares last traded at $1.36, with a volume of 14,367 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix presently has an average rating of “Sell”.

Read Our Latest Stock Report on PULM

Pulmatrix Stock Up 1.5%

The company has a market capitalization of $4.96 million, a P/E ratio of -1.11 and a beta of 1.94. The business has a fifty day moving average price of $1.43 and a 200 day moving average price of $2.51.

Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is currently owned by institutional investors and hedge funds.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).